This site is intended for healthcare professionals
Drug information

Flutiform

POM
Read time: 34 mins
Last updated: 01 Jul 2020
Published: 01 Jul 2020

4.1 Therapeutic indications

This fixed-dose combination of fluticasone propionate and formoterol fumarate (Flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:

• For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist.

Or

• For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.

Flutiform

50 microgram /5 microgram inhaler is indicated in adults, adolescents and children aged 5 years and above.

Flutiform

125 microgram /5 microgram inhaler is indicated in adults and adolescents aged 12 years and above.

Flutiform

250 microgram /10 microgram inhaler is indicated in adults only.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).